CSIMarket Company Name, Ticker, Suppliers, else..
 
Pulse Biosciences Inc   (NASDAQ: PLSE)
 

Pulse Biosciences Inc's Customers Performance

PLSE


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
PLSE's Source of Revenues During the corresponding time, Pulse Biosciences Inc sequentially revenue grew by 8.23 %. While revenue at the Pulse Biosciences Inc 's corporate clients

• List of PLSE Customers




for the same period Pulse Biosciences Inc sequentially revenue grew by 8.23 %.

• List of PLSE Customers

Pulse Biosciences Inc's Business Units
Single Reportable Segment    192.4 % of total Revenue






Pulse Biosciences Inc's Comment on Sales, Marketing and Customers



The company provides medical devices targeting specialists in soft tissue ablation and cardiac surgery. Their nPulse System has been placed at sites in the United States under evaluation and early commercial agreements, where initial patient treatments have been conducted. They initiated the PRECISE BTN clinical trial involving up to 50 patients across four sites to assess the safety and effectiveness of the Vybrance Percutaneous Electrode System for benign thyroid nodule soft tissue ablation. Over 300 patient procedures have been completed by clinicians participating in the Pilot Program and early commercial accounts. The company also offers nPulse cardiac products for cardiac surgeons treating atrial fibrillation (AF), including a surgical ablation clamp and an endocardial ablation catheter designed for safe and effective cardiac tissue ablation. The surgical clamp is intended for use during the Cox-Maze procedure, the standard surgical treatment for AF.


  News about Pulse Biosciences Inc Contracts

Pulsating Towards Innovation Pulse Biosciences Milestones in Cardiac and Soft Tissue Ablation

In the rapidly evolving field of medical technology, few innovations have garnered as much excitement as Pulse Biosciences, Inc.’s (Nasdaq: PLSE) recent breakthroughs in Nanosecond Pulsed Field Ablation (nsPFA). The company has made significant strides with two notable announcements: the commencement of a first-in-human feasibility study for a novel Cardiac Surgery System aimed at treating atrial fibrillation and the successful execution of the first U.S. procedure utilizing its CellFX nsPFA Percutaneous Electrode System. The Breakthrough in Cardiac TreatmentOn the cusp of revolutionary cardiac care, Pulse Biosciences has reported the successful treatment of two patients in a groundbreaking study using its...




Pulse Biosciences Inc’s Comment on Sales, Marketing and Customers


The company provides medical devices targeting specialists in soft tissue ablation and cardiac surgery. Their nPulse System has been placed at sites in the United States under evaluation and early commercial agreements, where initial patient treatments have been conducted. They initiated the PRECISE BTN clinical trial involving up to 50 patients across four sites to assess the safety and effectiveness of the Vybrance Percutaneous Electrode System for benign thyroid nodule soft tissue ablation. Over 300 patient procedures have been completed by clinicians participating in the Pilot Program and early commercial accounts. The company also offers nPulse cardiac products for cardiac surgeons treating atrial fibrillation (AF), including a surgical ablation clamp and an endocardial ablation catheter designed for safe and effective cardiac tissue ablation. The surgical clamp is intended for use during the Cox-Maze procedure, the standard surgical treatment for AF.







PLSE's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Pulse Biosciences Inc 3,376.27 2.76 -74.57 116
SUBTOTAL 0.00 0.00 0.00 -

Sources: Pulse Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Pulse Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Pulse Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.